Review
Open access
Sep 2026
Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma
It is concluded that biologic-enabled AIT is a promising but insufficiently defined strategy, and the prospective trials, standardized phenotyping, and safety registries needed to establish it as an evidence-based clinical pathway are outlined.
B. Jentzsch, A. Hoheisel, K. Gashynova et al.
· Frontiers in Allergy · 0 citations